Compare Heron Therapeutics Inc (HRTX) vs Vanguard Intermediate Term Corporate Bond ETF (VCIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Vanguard Intermediate Term Corporate Bond ETF — how do they compare? Heron Therapeutics Inc trades at $0.4 (market cap $68.01M), while Vanguard Intermediate Term Corporate Bond ETF trades at $78.38 (market cap $72.20B). The key difference: Vanguard Intermediate Term Corporate Bond ETF is far larger — about 1061.6× Heron Therapeutics Inc's market cap, and Vanguard Intermediate Term Corporate Bond ETF is more actively traded (7,532,796 versus 1,891,941). Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Vanguard Intermediate Term Corporate Bond ETF for 61 Days on average.
| HRTX | VCIT | |
|---|---|---|
Market Cap | $68.01M | $72.20B |
Volume | 1,891,941 | 7,532,796 |
Sector | Health | Fixed Income |
52-Week High | $1.49 | $84.82 |
52-Week Low | $0.27 | $77.98 |
Typical Hold Time | 35 Days | 61 Days |
Enterprise Value | $174.75M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) trades at $0.39, up 0.95% with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings discussions.
The outlook remains challenged by persistent losses and negative margins, though strong analyst support suggests potential upside. Key risks include execution on sales targets and achieving profitability. The stock's low price near 52-week lows presents speculative opportunity but requires careful risk management given financial performance.
VCIT trades at $78.345 with minimal daily movement (+0.1%). Technical indicators show a bearish trend with moving averages signaling caution, though oscillators are neutral. The ETF maintains consistent dividend distributions of $0.34 per share. Recent institutional interest includes Engineers Gate Manager LP's $1.27 million investment and HB Wealth Management's 242.9% position increase.
VCIT offers a compelling 4.8% yield with low 0.03% expense ratio, positioning it favorably against peers. However, bearish technical signals and interest rate sensitivity present near-term risks. The fund's intermediate-term corporate bond focus provides balanced risk-return profile for income-seeking investors in current economic conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Vanguard Intermediate Term Corporate Bond ETF
VCIT tracks the Bloomberg U.S. 5-10 Year Corporate Bond Index, providing exposure to investment-grade debt from industrial, utility, and financial companies. It acts as a middle-ground bond fund, offering higher yields than short-term bonds with less price volatility than long-term corporate debt.
Read more on VCIT →
